Moderna is trading at $237.92, with a -4.31% change, amid a broad risk-off session.
- The Nasdaq Composite is down 1.57% and the S&P 500 is down 0.95%, alongside higher oil prices and geopolitical concerns.
- Investors await additional Phase 3 melanoma-vaccine data scheduled for October 24. Coverage has described shares falling as investors await the presentation, but does not establish it as the direct cause of this decline.
- No clear new company-specific negative announcement surfaced in the search.